Induction of T helper 17 cell response by interleukin-7 in patients with primary cutaneous melanoma.
Journal
Melanoma research
ISSN: 1473-5636
Titre abrégé: Melanoma Res
Pays: England
ID NLM: 9109623
Informations de publication
Date de publication:
01 08 2021
01 08 2021
Historique:
pubmed:
1
6
2021
medline:
30
12
2021
entrez:
31
5
2021
Statut:
ppublish
Résumé
Interleukin (IL)-7 plays a vital role in proliferation and activation of T cells, however, its signaling through CD127 is impaired in T cells in cancers and chronic infections. The mechanisms underlying T helper 17 (Th17) cell responses by IL-7 in melanoma remain not fully understood. The aim of this study was to assess the effect of IL-7 signaling on Th17 responses in patients with primary cutaneous melanoma. Healthy and primary cutaneous melanoma donors were selected for this study of Th17 cell function. IL-17+CD4+ Th17 cells and CD127 expression on Th17 cells were determined by flow cytometry. Cytokine level was measured by ELISA. Peripheral and tissue-infiltrating CD4+ T cells were isolated using magnetic beads, and then stimulated with IL-7 and/or signal transducer and activator of transcription 5 inhibitor. Activated signaling molecules were analyzed by flow cytometry. Peripheral and tumor-infiltrating Th17 cells percentage was decreased, while peripheral IL-7 level was also reduced in melanoma patients. There was no significant difference of CD127 expression on Th17 cells between melanoma patients and controls. Antiapoptotic protein Bcl-2 was downregulated, whereas proapoptotic protein-activated caspase-3 was upregulated in peripheral and tissue-infiltrating Th17 cells in melanoma patients. Higher concentration of IL-7 (10 ng/mL), but not lower IL-7 concentration (1 ng/mL), promoted Bcl-2 expression and decreased caspase-3 expression in Th17 cells in melanoma patients. Inhibition of signal transducer and activator of transcription 5 resulted in the downregulation of Bcl-2 while upregulation of caspase-3 in Th17 cells. The present data suggested that reduced IL-7 responsiveness might be insufficient for Th17 activation in patients with primary cutaneous melanoma.
Identifiants
pubmed: 34054059
doi: 10.1097/CMR.0000000000000751
pii: 00008390-202108000-00006
doi:
Substances chimiques
Interleukin-7
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
328-337Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Orzan OA, Şandru A, Jecan CR. Controversies in the diagnosis and treatment of early cutaneous melanoma. J Med Life. 2015; 8:132–141
Rastrelli M, Tropea S, Rossi CR, Alaibac M. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In Vivo. 2014; 28:1005–1011
Dunki-Jacobs EM, Callender GG, McMasters KM. Current management of melanoma. Curr Probl Surg. 2013; 50:351–382
Dzwierzynski WW. Managing malignant melanoma. Plast Reconstr Surg. 2013; 132:446e–460e
Dowling J, McGregor SP, Williford P. Update on current treatment recommendations for primary cutaneous melanoma. Dermatol Clin. 2019; 37:397–407
Chen H, Yang M, Wang Q, Song F, Li X, Chen K. The new identified biomarkers determine sensitivity to immune check-point blockade therapies in melanoma. Oncoimmunology. 2019; 8:1608132
Nakamura Y. Biomarkers for immune checkpoint inhibitor-mediated tumor response and adverse events. Front Med (Lausanne). 2019; 6:119
Lin J, Zhu Z, Xiao H, Wakefield MR, Ding VA, Bai Q, Fang Y. The role of IL-7 in immunity and cancer. Anticancer Res. 2017; 37:963–967
Barata JT, Durum SK, Seddon B. Flip the coin: IL-7 and IL-7R in health and disease. Nat Immunol. 2019; 20:1584–1593
Oliveira ML, Akkapeddi P, Ribeiro D, Melão A, Barata JT. IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia: An update. Adv Biol Regul. 2019; 71:88–96
Crawley AM, Vranjkovic A, Faller E, McGuinty M, Busca A, Burke SC, et al. Jak/STAT and PI3K signaling pathways have both common and distinct roles in IL-7-mediated activities in human CD8+ T cells. J Leukoc Biol. 2014; 95:117–127
Chetoui N, Boisvert M, Gendron S, Aoudjit F. Interleukin-7 promotes the survival of human CD4+ effector/memory T cells by up-regulating Bcl-2 proteins and activating the JAK/STAT signalling pathway. Immunology. 2010; 130:418–426
Schadendorf D, Böhm M, Möller P, Grünewald T, Czarnetzki BM. Interleukin-7 induces differential lymphokine-activated killer cell activity against human melanoma cells, keratinocytes, and endothelial cells. J Invest Dermatol. 1994; 102:838–842
Miller AR, McBride WH, Dubinett SM, Dougherty GJ, Thacker JD, Shau H, et al. Transduction of human melanoma cell lines with the human interleukin-7 gene using retroviral-mediated gene transfer: comparison of immunologic properties with interleukin-2. Blood. 1993; 82:3686–3694
Côté SC, Stilla A, Burke Schinkel SC, Berthoud TK, Angel JB. IL-7-induced proliferation of peripheral Th17 cells is impaired in HAART-controlled HIV infection. AIDS. 2019; 33:985–991
Hou H, Kang Y, Zeng Y, Li Y, Shang J. Interleukin-7 augments CD8+ T cells function and promotes viral clearance in chronic hepatitis C virus infection. Cytokine. 2018; 102:26–33
Teng D, Ding L, Cai B, Luo Q, Wang H. Interleukin-7 enhances anti-tumor activity of CD8+ T cells in patients with hepatocellular carcinoma. Cytokine. 2019; 118:115–123
Duan MC, Zhong XN, Liu GN, Wei JR. The Treg/Th17 paradigm in lung cancer. J Immunol Res. 2014; 2014:730380
Joerger M, Finn SP, Cuffe S, Byrne AT, Gray SG. The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy?. Expert Opin Ther Targets. 2016; 20:1339–1356
Zhang JP, Yan J, Xu J, Pang XH, Chen MS, Li L, et al. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol. 2009; 50:980–989
Hasan I, Gani RA, Lesmana LA, Kresno SB, Pandelaki J, Suwarto S. The association between peripheral Th17, Th1, IL-17, and IFN-γ levels and TACE response in patients with unresectable hepatocellular carcinoma with or without cirrhosis. Acta Med Indones. 2020; 52:326–333
Yang L, Qi Y, Hu J, Tang L, Zhao S, Shan B. Expression of Th17 cells in breast cancer tissue and its association with clinical parameters. Cell Biochem Biophys. 2012; 62:153–159
Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res. 2011; 71:1263–1271
He S, Fei M, Wu Y, Zheng D, Wan D, Wang L, Li D. Distribution and clinical significance of Th17 cells in the tumor microenvironment and peripheral blood of pancreatic cancer patients. Int J Mol Sci. 2011; 12:7424–7437
Chang SH. T helper 17 (Th17) cells and interleukin-17 (IL-17) in cancer. Arch Pharm Res. 2019; 42:549–559
Martiniuk F, Damian DL, Thompson JF, Scolyer RA, Tchou-Wong KM, Levis WR. TH17 is involved in the remarkable regression of metastatic malignant melanoma to topical diphencyprone. J Drugs Dermatol. 2010; 9:1368–1372
Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser A, et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood. 2008; 112:362–373
Chen C, Gao FH. Th17 cells paradoxical roles in melanoma and potential application in immunotherapy. Front Immunol. 2019; 10:187
Dulos J, Carven GJ, van Boxtel SJ, Evers S, Driessen-Engels LJ, Hobo W, et al. PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J Immunother. 2012; 35:169–178
von Euw E, Chodon T, Attar N, Jalil J, Koya RC, Comin-Anduix B, Ribas A. CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J Transl Med. 2009; 7:35
Li S, Wang Z, Zhang G, Fu J, Zhang X. Interleukin-7 promotes lung-resident CD14+ monocytes activity in patients with lung squamous carcinoma. Int Immunopharmacol. 2019; 67:202–210
Zhang ZH, Jiang BC, Liu XH, Zhang MX, Li ZS, Zhu GZ. Interleukin-7 regulates T follicular helper cell function in patients with chronic hepatitis C. Viral Immunol. 2018; 31:417–425
Pellegrini M, Calzascia T, Toe JG, Preston SP, Lin AE, Elford AR, et al. IL-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology. Cell. 2011; 144:601–613
Parish IA, Kaech SM. IL-7 knocks the socs off chronic viral infection. Cell. 2011; 144:467–468
Yeon SM, Halim L, Chandele A, Perry CJ, Kim SH, Kim SU, et al. IL-7 plays a critical role for the homeostasis of allergen-specific memory CD4 T cells in the lung and airways. Sci Rep. 2017; 7:11155
Zhang X, Zhang M, Jiang M, Nong G. Effect of IL-7 on Th17 cell responses in a mouse model of neutrophilic asthma. Mol Med Rep. 2020; 22:1205–1212
Janumyan YM, Sansam CG, Chattopadhyay A, Cheng N, Soucie EL, Penn LZ, et al. Bcl-xL/Bcl-2 coordinately regulates apoptosis, cell cycle arrest and cell cycle entry. EMBO J. 2003; 22:5459–5470
Goodsell DS. The molecular perspective: Bcl-2 and apoptosis. Stem Cells. 2002; 20:355–356
Bednarz-Misa I, Bromke MA, Krzystek-Korpacka M. Interleukin (IL)-7 signaling in the tumor microenvironment. Adv Exp Med Biol. 2021; 1290:9–49
Hu X, Yuan L, Ma T. Mechanisms of JAK-STAT signaling pathway mediated by CXCL8 gene silencing on epithelial-mesenchymal transition of human cutaneous melanoma cells. Oncol Lett. 2020; 20:1973–1981